CESSATECH
CESSATECH
Industry:
Medical Pharmaceutical
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.cessatech.com
Status:
Active
Contact:
45 9387 2309
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Tag Manager WordPress Font Awesome Sitelinks Search Box Organization Schema Yoast WordPress SEO Plugin Yoast SEO Premium
Similar Organizations
ATGC
ATGC engages in the research and development of drugs.
Official Site Inspections
http://www.cessatech.com
- Host name: linux301.unoeuro.com
- IP address: 93.191.156.191
- Location: Langeskov Denmark
- Latitude: 55.3565
- Longitude: 10.5845
- Timezone: Europe/Copenhagen
- Postal: 5550
More informations about "Cessatech"
Cessatech - Rethinking Child Treatments
Lead Asset CT001 – Nasal spray. Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or …See details»
About - Cessatech
Cessatech Colored Cessatech’s business model offers unique, scalable economic value creation by identifying and developing drugs with a short time to market and risk-reduced profile. The …See details»
Cessatech - Crunchbase Company Profile & Funding
Organization. Cessatech . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Cessatech is a pharmaceutical firm that …See details»
Cessatech - 2025 Company Profile, Funding & Competitors - Tracxn
3 days ago Cessatech announces that recruitment has today reached the halfway point for patient recruitment with 75 included patients in the Paediatric Study 0202Cision • Oct 16, 2024 …See details»
Second quarter report Q2-2022 – green light for the ... - Cessatech
Cessatech A/S - Kanonbådsvej 2, DK-1437 Copenhagen - [email protected] - Cvr 4129 3055. 2 Second Quarter Report (Q2-2022) ... We are still a small organization, and we continue to …See details»
Cessatech | CEO Jes Trygved about the company and …
00:00 - Intro00:20 - About Cessatech01:05 - CT001 Nasal Spray pain reliever for children02:48 - Why is there a gap on treatments for children03:05 - Why do a...See details»
Cessatech A/S publishes Annual Report for the fiscal year 2024
Feb 28, 2025 The report is also available on Cessatech's website www.cessatech.com under `Fillings & Reports'. Full year 2024 for the period 1 January - 31 December (Q4'2024 results in …See details»
Cessatech A/S (CESSA.CO)
Find the latest Cessatech A/S (CESSA.CO) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Cessatech A/S publishes Annual Report for the fiscal year 2023
Cessatech A/S - Kanonbådsvej 2, DK-1437 Copenhagen - [email protected] - CVR 4129 30552 The annual report is presented for approval at the Annual General Meeting, 27 March …See details»
Cessatech: Annual General Meeting - 28 March 2025
Mar 12, 2025 Cessatech A/S is a Danish pharmaceutical company committed to developing and commercializing evidence-based and innovative medicines for children for the treatment of …See details»
Cessatech - Cision News
Cessatech A/S (“Cessatech” or the “Company”) hereby convenes the annual general meeting to be held on 27 March 2024. The shareholders of Cessatech A/S The board of directors hereby …See details»
Q&A Selected top 10 investor questions - Cessatech
Cessatech and Proveca partnership - Q&A Selected top 10 investor questions 1. How many potential partners have you had dialogue with for Europe? A: We have had several …See details»
Cessatech A/S - Facebook
Cessatech A/S, Copenhagen. 57 likes · 7 talking about this. Developing evidence based medicineSee details»
Cessatech updates the milestones for the coming year
CessatechOn 23 December – Cessatech A/S (“Cessatech” or “the Company”) gives an update on the major milestones for the coming year. We are very pleased with the progress Cessatech …See details»
Cessatech presents key expected milestones for 2025
Dec 23, 2024 During the year, the research company Cessatech achieved an important milestone in the agreement to commercialize CT001 with Provenca. The milestone is seen as …See details»
Positive Notified Body opinion under MDR for CT001 - Cessatech
Published: 4. February, 2025. On 4 February – Cessatech A/S (“Cessatech” or “the Company”) announces that the Company… On 4 February – Cessatech A/S (“Cessatech” or “the …See details»
Cessatech skriver kommersialiseringsavtal för CT001 med Proveca
Aug 26, 2024 Forskningsbolaget Cessatech har skrivit på ett exklusivt kommersialiseringsavtal med Proveca för CT001, framgår det av ett pressmeddelande. Avtalet gäller för hela världen …See details»
Riktkurs Cessatech | Aktuell data och historik - Börskollen
Riktkurser för Cessatech. Senaste riktkurs, riktkurs konsensus och riktkurs sentiment för Cessatech. Allt samlat på ett ställe. Börskollen För dig med koll på börsen. TIPS Ladda ner vår …See details»
Cessatech announces that the Paediatric Committee has agreed to …
Cessatech A/S - Kanonbådsvej 2, DK-1437 Copenhagen - [email protected] - Cvr 4129 3055 EMA’s Paediatric Committee, CT001 is now one step closer to finalize the clinical program and …See details»
Third quarter report Q3-2022 - Cessatech
The Board of Directors and CEO of Cessatech hereby publish the third quarter report of 2022. In this interim report, the following definitions apply, unless stated otherwise: The “Company” or …See details»